Mark Pollack to Melanoma
This is a "connection" page, showing publications Mark Pollack has written about Melanoma.
Connection Strength
0.606
-
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018 01 01; 29(1):250-255.
Score: 0.606
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.